Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 13, 2024, discloses the vesting of Performance Share Plan (PSP) awards granted in 2021 to Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs). The performance period covered January 1, 2021, through December 31, 2023. The filing details the vesting outcomes based on specific business performance conditions and the subsequent sale of shares to meet tax liabilities.
Key Financial Metrics and Performance Outcomes
The filing provides specific performance metrics used to determine vesting levels for the 2021 awards. The overall vesting level for the 2021 award was 69.95%, with 30.05% lapsed.
- Adjusted Free Cash Flow: The Company achieved £9.81 billion for the three years ending December 31, 2023, exceeding the revised maximum vesting target of £6.54 billion. This resulted in 100% vesting for the 30% portion of the award tied to this metric.
- Total Shareholder Return (TSR): GSK ranked 9th against a comparator group of 10 global pharmaceutical companies. This result fell below the threshold vesting level, resulting in 0% vesting for the 30% portion of the award tied to this metric.
- Innovation Sales: The Company achieved revenues from new products of £18.651 billion. This was slightly below the £18.667 billion required for 100% vesting but above the £15.273 billion threshold. This resulted in 99.77% vesting for the 20% portion of the award.
- Pipeline Progress: The measure, equally weighted between pivotal trial starts and major regulatory approvals, achieved 100% vesting for the 20% portion of the award.
Share Prices on Vesting Date (February 9, 2024):
- Ordinary Shares: £16.60
- American Depositary Shares (ADSs): $41.91
Material Changes and Transactions
The filing details specific transactions executed on February 9, 2024, for various executives. These transactions involved the vesting of shares (recorded at £0.00 or $0.00) and the immediate sale of a portion of those shares to cover tax liabilities.
Key transactions included:
- Emma Walmsley (CEO): 441,309 Ordinary Shares vested.
- Diana Conrad (Chief People Officer): 89,414 Ordinary Shares vested; 47,864 shares sold at £16.6055.
- James Ford (SVP, Legal): 139,077 Ordinary Shares vested; 65,367 shares sold at £16.6055.
- Shobie Ramakrishnan (Chief Digital Officer): 5,383 ADSs vested; 2,894 ADSs sold at $41.84.
- Hal Barron (Non-Executive Director): 107,377 ADSs vested; 57,716 ADSs sold at $41.84.
Similar vesting and tax sale transactions were reported for Luke Miels, Regis Simard, Phil Thomson, Deborah Waterhouse, Tony Wood, Victoria Whyte, and Dylan Jackson (PCA).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the standard disclosure of performance conditions. It notes that vested shares for Executive Directors are subject to an additional two-year vesting period (hold period). The filing references the 2022 Annual Report for details on adjustments to the original target and vesting schedule.
Investor Verification Checklist
- Verify the specific performance targets and vesting schedules detailed in the 2022 Annual Report to understand the "revised amount" for Adjusted Free Cash Flow.
- Confirm the composition of the comparator group used for the Total Shareholder Return (TSR) ranking to assess the competitiveness of the 9th place finish.
- Review the definition of "Innovation Sales" to understand the product mix contributing to the £18.651 billion figure.
- Monitor the two-year hold period for Executive Directors to understand future potential selling pressure.
- Check subsequent filings for the actual release of shares held by Executive Directors after the two-year period expires.